Cellular senescence in giant cell arteritis and polymyalgia rheumatica: From mechanisms to therapeutic opportunities
European Journal of Clinical Investigation · 2026-01 · 56 (1)
DOI: 10.1111/eci.70166 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 24.12.2025. Verfasst von Yiting Luo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Giant Cell Arteritis, Polymyalgia Rheumatica, Cellular Senescence, Senescence-Associated Secretory Phenotype. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: Young Talents in medical and health care under the Special Support Program for High-level Talents in Zhejiang Province, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Giant cell arteritis (GCA) and (PMR) are inflammatory rheumatic disorders whose pathogenesis are unclear. The interleukin (IL)‐6 receptor inhibitor is the first approved biologic agent for GCA and PMR, reducing relapse rates and cumulative glucocorticoid (GC) doses. Notably, IL‐6, also a key pro‐inflammatory factor secreted by senescent cells, contributes to tissue aging and chronic inflammation. We aim to explore the role of senescence‐associated secretory phenotype (SASP) in the pathogenesis of GCA and PMR.
Methods
A narrative synthesis of literature published in the last 10 years was conducted utilizing keywords such as “Giant cell arteritis,” “Polymyalgia rheumatica,” “cellular senescence,” “senescence‐associated secretory phenotype,” or “aging”.
Results
Evidence links cellular senescence and SASP to the pathogenesis of GCA and PMR, with key components like IL‐6, IL‐1β, and matrix metalloproteinases (MMPs) driving inflammation and tissue damage. We highlight how key SASP components, such as IL‐6, IL‐1β, and MMPs promote inflammation and tissue damage in GCA and PMR. Targeting SASP factors (senomorphics) or selectively eliminating senescent cells (senolytics) offers therapeutic potential. Further research into the mechanisms linking senescence to disease phenotypes is needed to develop effective therapies that mitigate disease progression and improve clinical outcomes.
Conclusion
We demonstrated age‐related stress and senescence in the pathogenesis of GCA and PMR. We provide an overview of senomorphics, which have shown promise in clinical trials, and emphasize the need for further research to develop effective therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
ORCID-Profile: Weiqian Chen
Förderung
- Young Talents in medical and health care under the Special Support Program for High-level Talents in Zhejiang Province
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Luo, Y., Yang, F., He, Y., Lin, J., & Chen, W. (2026). Cellular senescence in giant cell arteritis and polymyalgia rheumatica: From mechanisms to therapeutic opportunities. European Journal of Clinical Investigation, 56(1). https://doi.org/10.1111/eci.70166
Vancouver
Luo Y, Yang F, He Y, Lin J, Chen W. Cellular senescence in giant cell arteritis and polymyalgia rheumatica: From mechanisms to therapeutic opportunities. European Journal of Clinical Investigation. 2026;56(1). doi:10.1111/eci.70166
BibTeX
@article{Luo2026,
author = {Luo, Yiting and Yang, Fan and He, Yanlin and Lin, Jin and Chen, Weiqian},
title = {Cellular senescence in giant cell arteritis and polymyalgia rheumatica: From mechanisms to therapeutic opportunities},
journal = {European Journal of Clinical Investigation},
year = {2026},
volume = {56},
number = {1},
doi = {10.1111/eci.70166}
}
EUVIMED